Neuropathic Pain Treatment Update : an overview of recent neuropathic pain treatments show especially sodium channel blockers are hot in the early clinic.

Neuropathic Pain Treatments Update at NeuPsych 2017

At the at plenary session of the NeuPsych 2017 at Gothenburg, Sweden (June 2017) an overview was given of all new treatments in neuropathic pain. There were only 2 Industry Sponsors at the NeuPsych and no industry sponsored symposia. Perhaps NeuPsych had to compete with EFIC (September 2017, Denmark) was a suggestion heard.

1891415-Sebastian-Kaulitzki-Dreamstime-INP Neuropathic Pain Treatment Update 2017

At the Plenary Session III Chaired by Andrea Truini and Volker Tronnier, professor Didier Bouhassira from France presented a state-of-the-art lecture on: ‘New Treatments for Neuropathic Pain’.

Neuropathic Pain Treatments Update

Bouhassira started pointing out that there is not much news in general. He pointed out that new treatments for old drugs are quite important in the dessert currently of new treatment options (repositioning).

Of course there are some new molecules, such as MAP kinase inhibitors and Nerve Growth Factors, Tumor Necrosis Factor Receptor Superfamily Member 16, Bradykinin B1 Receptor, Opioid Receptor-Like-1 Receptor, Purinoceptors, Metabotropic Glutamate Receptors 6 and 7, Calcitonin Gene-Related Peptide Type-1 Receptors etc.

Preclinical data

However, most of these are in preclinical phase. At an earlier workshop it was stipulated how much of these preclinical data are difficult to relay on. Due to the lack of replication data, absence of blinded rating and other methodological issues.

Only two recent papers are remarkable according to the speaker and were referred to. Both on the clinical data related to a new sodium channel blocker, TV-45070 drug from TEVA. This sodium channel blocker is currently analyzed in a Phase 2b study in post herpetic neuralgia (PHN).

The new indications for old drugs (repositioning) chapter was illustrated by a second example, botulum BTX-A role in neuropathic pain.

Interestingly earlier at the Congress new clinical data were presented at a workshop on the sodium channel target, on the old drug and sodium channel blocker phenytoin [1]. Currently under development via a patented repositioning strategy by Topical Innovations for neuropathic pain.

Non-pharmacological treatments of Neuropathic Pain

Furthermore, he discussed some non-pharmacological treatments based on repetitive trans cranial magnetic stimulation (r-TMS), which possibly might work via long lasting neuroplastic effects.

Naloxone can reverse the r-TMS effects. At least 20 controlled studies have supported this method, and especially frequenties higher than 5Hz seems useful. The long term effects however are still quite unknown.

Transcranial direct current stimulation (tDCs) is a second non-invasive technique, and at the poster sessions the inhalation of NO was presented in neuropathic pain patients, with good effects in preliminary tests.

Gotenburg, June 16th 2017, Jan M Keppel Hesselink, MD, PhD
‘Neuropathic Pain Treatment Update at NeuPSIG 2017’

Watch our video’s about Neuropathy.

Glia modulators for neuropathic pain

Psoriasis: a new innovative approach
Statins side effects: myalgia and myopathy
Nitrates in neuropathic pain?


Referentielijst

[1] Keppel Hesselink JM1. | Phenytoin: a step by step insight into its multiple mechanisms of action-80years of mechanistic studies in neuropharmacology. | J Neurol. | 2017 Mar 27. doi: 10.1007/s00415-017-8465-4. [Epub ahead of print]


Wat kunnen wij voor u betekenen?

Wat kunnen wij voor u betekenen?

Ik ga akkoord met de privacyverklaring*